Gyroscope Therapeutics Limited
Clinical trials sponsored by Gyroscope Therapeutics Limited, explained in plain language.
-
Gene therapy injection tested to halt blinding eye disease
Disease control TerminatedThis study tested whether a single injection of an experimental gene therapy called GT005 could safely slow the progression of geographic atrophy, an advanced form of dry age-related macular degeneration that causes permanent vision loss. About 98 participants with this condition…
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Apr 02, 2026 04:12 UTC
-
First human test of gene injection aims to halt blinding eye disease
Disease control TerminatedThis early-stage study tested a new gene therapy called GT005 for people with an advanced form of dry age-related macular degeneration (AMD) that causes vision loss. The therapy involved a single injection into the back of the eye, aiming to deliver a gene that might help control…
Phase: PHASE1, PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Gene therapy trial for blinding eye disease halted
Disease control TerminatedThis study tested whether a single injection of an experimental gene therapy called GT005 could slow the progression of geographic atrophy, a form of advanced dry age-related macular degeneration (AMD) that causes permanent vision loss. About 255 participants with this condition …
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC